Ajanta Pharma signs pact with Biocon to sell semaglutide in 26 countries | Company News
Mumbai-based drugmaker Ajanta Pharma on Tuesday entered into an in-licensing agreement with Biocon to commercialise its version of blockbuster molecule semaglutide, the active ingredient in weight-loss and diabetes drugs Wegovy and Ozempic. What does the Ajanta–Biocon agreement cover? As part of the pact, Biocon will be responsible for supplying semaglutide to…